Treatment of hepatitis C in renal transplantation candidates

A single-center experience

T. Werner, Bashar Aqel, Vijayan Balan, Thomas Byrne, Elizabeth Carey, David Douglas, Raymond L. Heilman, Jorge Rakela, Kristin Mekeel, Kunam Sudhakar Reddy, Hugo E Vargas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. There is no consensus on hepatitis C virus (HCV) treatment in patients with renal failure. Toxicity of pegylated interferon (PEG-IFN) and ribavirin limit options; hence the ideal approach for therapy in these patients deserves attention. We report the results of kidney transplantation (KTx) candidates infected with HCV treated with PEG-IFN monotherapy. Methods. KTx candidates with HCV infection treated with PEG-IFN monotherapy between January 2001 and February 2009 were included. Liver biopsies were performed before therapy. Response was assessed using accepted virological time points. Results. From 2636 patients listed for KTx, 60 patients were tested positive for anti-HCV. Twenty-two patients were eligible for treatment. All patients were HCV treatment naïve. One patient had biopsy-confirmed cirrhosis. Mean Ishak-Knodell fibrosis stage was 1.3. Ten patients (45%) achieved sustained viral response. In genotype 1 patients, there were no relapsers among early responders, despite the limited regimen. Nine patients (40%) in the cohort have had KTx. Of these, there were four responders and five nonresponders. None of the responders have had recurrence of their HCV after their KTx. Conclusions. End-stage renal disease patients with HCV can be treated successfully with PEG-IFN monotherapy. Our sustained viral response rate was 45% (10/22) in patients treated before KTx.

Original languageEnglish (US)
Pages (from-to)407-411
Number of pages5
JournalTransplantation
Volume90
Issue number4
DOIs
StatePublished - Aug 27 2010

Fingerprint

Hepatitis C
Kidney Transplantation
Hepacivirus
Interferons
Therapeutics
Fibrosis
Biopsy
Ribavirin
Virus Diseases
Chronic Kidney Failure
Renal Insufficiency
Genotype
Recurrence

Keywords

  • End-stage renal disease
  • Hepatitis C
  • Kidney transplantation
  • Pegylated interferon monotherapy

ASJC Scopus subject areas

  • Transplantation

Cite this

Treatment of hepatitis C in renal transplantation candidates : A single-center experience. / Werner, T.; Aqel, Bashar; Balan, Vijayan; Byrne, Thomas; Carey, Elizabeth; Douglas, David; Heilman, Raymond L.; Rakela, Jorge; Mekeel, Kristin; Reddy, Kunam Sudhakar; Vargas, Hugo E.

In: Transplantation, Vol. 90, No. 4, 27.08.2010, p. 407-411.

Research output: Contribution to journalArticle

Werner, T, Aqel, B, Balan, V, Byrne, T, Carey, E, Douglas, D, Heilman, RL, Rakela, J, Mekeel, K, Reddy, KS & Vargas, HE 2010, 'Treatment of hepatitis C in renal transplantation candidates: A single-center experience', Transplantation, vol. 90, no. 4, pp. 407-411. https://doi.org/10.1097/TP.0b013e3181e72837
Werner, T. ; Aqel, Bashar ; Balan, Vijayan ; Byrne, Thomas ; Carey, Elizabeth ; Douglas, David ; Heilman, Raymond L. ; Rakela, Jorge ; Mekeel, Kristin ; Reddy, Kunam Sudhakar ; Vargas, Hugo E. / Treatment of hepatitis C in renal transplantation candidates : A single-center experience. In: Transplantation. 2010 ; Vol. 90, No. 4. pp. 407-411.
@article{511ccccce8624accbc25a72bf7584cbb,
title = "Treatment of hepatitis C in renal transplantation candidates: A single-center experience",
abstract = "Background. There is no consensus on hepatitis C virus (HCV) treatment in patients with renal failure. Toxicity of pegylated interferon (PEG-IFN) and ribavirin limit options; hence the ideal approach for therapy in these patients deserves attention. We report the results of kidney transplantation (KTx) candidates infected with HCV treated with PEG-IFN monotherapy. Methods. KTx candidates with HCV infection treated with PEG-IFN monotherapy between January 2001 and February 2009 were included. Liver biopsies were performed before therapy. Response was assessed using accepted virological time points. Results. From 2636 patients listed for KTx, 60 patients were tested positive for anti-HCV. Twenty-two patients were eligible for treatment. All patients were HCV treatment na{\"i}ve. One patient had biopsy-confirmed cirrhosis. Mean Ishak-Knodell fibrosis stage was 1.3. Ten patients (45{\%}) achieved sustained viral response. In genotype 1 patients, there were no relapsers among early responders, despite the limited regimen. Nine patients (40{\%}) in the cohort have had KTx. Of these, there were four responders and five nonresponders. None of the responders have had recurrence of their HCV after their KTx. Conclusions. End-stage renal disease patients with HCV can be treated successfully with PEG-IFN monotherapy. Our sustained viral response rate was 45{\%} (10/22) in patients treated before KTx.",
keywords = "End-stage renal disease, Hepatitis C, Kidney transplantation, Pegylated interferon monotherapy",
author = "T. Werner and Bashar Aqel and Vijayan Balan and Thomas Byrne and Elizabeth Carey and David Douglas and Heilman, {Raymond L.} and Jorge Rakela and Kristin Mekeel and Reddy, {Kunam Sudhakar} and Vargas, {Hugo E}",
year = "2010",
month = "8",
day = "27",
doi = "10.1097/TP.0b013e3181e72837",
language = "English (US)",
volume = "90",
pages = "407--411",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment of hepatitis C in renal transplantation candidates

T2 - A single-center experience

AU - Werner, T.

AU - Aqel, Bashar

AU - Balan, Vijayan

AU - Byrne, Thomas

AU - Carey, Elizabeth

AU - Douglas, David

AU - Heilman, Raymond L.

AU - Rakela, Jorge

AU - Mekeel, Kristin

AU - Reddy, Kunam Sudhakar

AU - Vargas, Hugo E

PY - 2010/8/27

Y1 - 2010/8/27

N2 - Background. There is no consensus on hepatitis C virus (HCV) treatment in patients with renal failure. Toxicity of pegylated interferon (PEG-IFN) and ribavirin limit options; hence the ideal approach for therapy in these patients deserves attention. We report the results of kidney transplantation (KTx) candidates infected with HCV treated with PEG-IFN monotherapy. Methods. KTx candidates with HCV infection treated with PEG-IFN monotherapy between January 2001 and February 2009 were included. Liver biopsies were performed before therapy. Response was assessed using accepted virological time points. Results. From 2636 patients listed for KTx, 60 patients were tested positive for anti-HCV. Twenty-two patients were eligible for treatment. All patients were HCV treatment naïve. One patient had biopsy-confirmed cirrhosis. Mean Ishak-Knodell fibrosis stage was 1.3. Ten patients (45%) achieved sustained viral response. In genotype 1 patients, there were no relapsers among early responders, despite the limited regimen. Nine patients (40%) in the cohort have had KTx. Of these, there were four responders and five nonresponders. None of the responders have had recurrence of their HCV after their KTx. Conclusions. End-stage renal disease patients with HCV can be treated successfully with PEG-IFN monotherapy. Our sustained viral response rate was 45% (10/22) in patients treated before KTx.

AB - Background. There is no consensus on hepatitis C virus (HCV) treatment in patients with renal failure. Toxicity of pegylated interferon (PEG-IFN) and ribavirin limit options; hence the ideal approach for therapy in these patients deserves attention. We report the results of kidney transplantation (KTx) candidates infected with HCV treated with PEG-IFN monotherapy. Methods. KTx candidates with HCV infection treated with PEG-IFN monotherapy between January 2001 and February 2009 were included. Liver biopsies were performed before therapy. Response was assessed using accepted virological time points. Results. From 2636 patients listed for KTx, 60 patients were tested positive for anti-HCV. Twenty-two patients were eligible for treatment. All patients were HCV treatment naïve. One patient had biopsy-confirmed cirrhosis. Mean Ishak-Knodell fibrosis stage was 1.3. Ten patients (45%) achieved sustained viral response. In genotype 1 patients, there were no relapsers among early responders, despite the limited regimen. Nine patients (40%) in the cohort have had KTx. Of these, there were four responders and five nonresponders. None of the responders have had recurrence of their HCV after their KTx. Conclusions. End-stage renal disease patients with HCV can be treated successfully with PEG-IFN monotherapy. Our sustained viral response rate was 45% (10/22) in patients treated before KTx.

KW - End-stage renal disease

KW - Hepatitis C

KW - Kidney transplantation

KW - Pegylated interferon monotherapy

UR - http://www.scopus.com/inward/record.url?scp=77955983140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955983140&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e3181e72837

DO - 10.1097/TP.0b013e3181e72837

M3 - Article

VL - 90

SP - 407

EP - 411

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -